Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Retained Earnings (2019 - 2026)

Atea Pharmaceuticals' Retained Earnings history spans 8 years, with the latest figure at -$97000.0 for Q1 2026.

  • Quarterly Retained Earnings rose 99.98% to -$97000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$97000.0 through Mar 2026, up 99.98% year-over-year, with the annual reading at -$522.6 million for FY2025, 43.48% down from the prior year.
  • Retained Earnings came in at -$97000.0 for Q1 2026, up from -$522.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $14.0 million in Q1 2022 to a low of -$522.6 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$17.4 million (2022), against an average of -$110.9 million.
  • Year-over-year, Retained Earnings soared 140.51% in 2022 and then plummeted 220061.33% in 2025.
  • Atea Pharmaceuticals' Retained Earnings stood at -$684000.0 in 2022, then plummeted by 28530.85% to -$195.8 million in 2023, then plummeted by 85.98% to -$364.2 million in 2024, then plummeted by 43.48% to -$522.6 million in 2025, then soared by 99.98% to -$97000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Retained Earnings are -$97000.0 (Q1 2026), -$522.6 million (Q4 2025), and $238000.0 (Q3 2025).